EU Commission approves AstraZeneca’s Klygefa for adult generalized myasthenia gravis

AstraZeneca’s Alexion unit received European Commission approval on 16 November 2026 for Klygefa (gefurulimab) as an add‑on therapy for adults with anti‑acetylcholine‑receptor‑positive generalized myasthenia gravis (gMG). The decision was based on the PREVAIL Phase III trial, which showed a statistically significant improvement in Myasthenia Gravis Activities of Daily Living (MG‑ADL) score at week 26 versus placebo. Klygefa is the first dual‑binding nanobody C5 inhibitor approved in the EU and will be administered once weekly by subcutaneous autoinjector.

The approval adds a major regional authorisation for a rare‑disease product, expanding AstraZeneca’s gMG portfolio into the EU market (the company notes the decision adds a “major regional authorisation”). This could generate new sales revenue from an estimated 82,500 gMG patients in five EU countries, of whom about 66,000 are AChR‑positive. (source 2)

  • 1The European Commission approved Klygefa on 16 November 2026.
  • 2Klygefa is indicated for adults with anti‑AChR‑positive generalized myasthenia gravis as an add‑on to standard therapy.
  • 3The PREVAIL Phase III trial enrolled 260 patients (131 gefurulimab, 129 placebo) across 20 countries.
  • 4At week 26 the least‑squares mean change in MG‑ADL score was –4.2 points with gefurulimab versus –2.6 with placebo, a treatment difference of –1.6 points (95 % CI –2.4 to –0.8, p < 0.001).
  • 5AstraZeneca estimates 82,500 gMG patients in Germany, France, the UK, Italy and Spain, including approximately 66,000 AChR‑positive patients.
  • 6Klygefa is the first and only approved dual‑binding nanobody C5 inhibitor in the EU, administered once weekly by subcutaneous autoinjector.

Sources